Summit Therapeutics Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Financial amounts below are in U.S. dollars; amounts are shown in millions unless otherwise noted.
Business context
Summit is a clinical-stage biopharmaceutical company that shifted its focus from anti-infectives to oncology after closing its license agreement with Akeso for ivonescimab (SMT112) in January 2023. Summit holds development and commercialization rights in the United States, Canada, Europe, and Japan. It is winding down ridinilazole development and reviewing anti-infectives programs for potential partnerships.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $0 | $0.25 |
| Research and development expense | $9.9 | $20.6 |
| In-process research and development expense | $520.9 | — |
| General and administrative expense | $6.9 | $6.7 |
| Operating loss | $537.2 | $22.2 |
| Net loss | $542.4 | $21.4 |
| Basic and diluted loss per share | $1.43 | $0.15 |
| Cash used in operating activities | $13.1 | $19.0 |
The $520.9 million in-process R&D charge reflects the Akeso license consideration and related costs, primarily $474.9 million paid in cash, $45.9 million in Summit shares, and $0.1 million of transaction costs. The resulting net loss is therefore dominated by this upfront, non-recurring license expense; it is not a measure of recurring operating cash burn. No product revenue was reported, and gross margin is not meaningful.
At March 31, 2023, Summit had cash and cash equivalents of $71.0 million, short-term U.S. Treasury investments of $171.0 million, and U.K. R&D tax-credit receivables totaling $5.0 million. Current assets were $248.0 million and current liabilities $17.4 million. Operating cash use was $13.1 million; investing cash use was $645.1 million, including $475.0 million of cash payments to Akeso and $170.0 million invested in Treasury securities. Financing provided $80.1 million, principally from the rights offering, net of related-party note repayments and other financing items.
Related-party promissory notes outstanding totaled $100.0 million at quarter-end, due in 2024; current debt was zero. Interest expense on related-party notes was $8.3 million for the quarter. Stockholders’ equity was $133.5 million and accumulated deficit was $920.7 million.
Material changes versus the prior period
- Revenue fell from $0.25 million to zero; the prior-period amount related to the Eurofarma ridinilazole agreement, and Summit does not anticipate further milestones under that agreement.
- R&D expense declined by $10.7 million, mainly as anti-infectives development wound down, partly offset by $2.4 million of oncology spending. G&A expense increased by $0.2 million.
- Other operating income declined from $4.8 million to $0.6 million, reflecting the end of BARDA and CARB-X funding and lower R&D tax credits.
- The $500 million rights offering issued 476.2 million shares at $1.05 per share, with $619,000 of issuance costs. Total shares issued and outstanding rose from 211.1 million at year-end 2022 to 697.7 million at March 31, 2023; reported shares outstanding as of May 4, 2023 were also 697.7 million.
- Summit repaid the $20 million Zanganeh note and settled the $400 million Duggan note using rights-offering proceeds and a $395.3 million noncash extinguishment for shares subscribed by Mr. Duggan. The remaining $100 million Duggan note is related-party debt.
Outlook, risks, and other notable items
- Management stated that existing cash, cash equivalents, and U.K. R&D tax credits were expected to fund planned ivonescimab clinical-trial operating costs and working capital for at least 12 months from issuance of the financial statements, with the MD&A describing the runway as extending into the second half of 2024. The estimate depends on assumptions and could prove shorter.
- Summit expects continued operating losses and says it will need additional capital. Management believed financing could be available before the second half of 2024, but gave no assurance of availability or acceptable terms. Failure to secure funds could delay, reduce, or terminate programs; equity financing could dilute shareholders.
- Akeso may receive up to $4.5 billion in additional regulatory and commercial milestones, plus low double-digit royalties on net sales. The filing says the amount, timing, and likelihood of contingent payments cannot currently be estimated. Manufacturing and purchase commitments also apply.
- On May 3, 2023, Summit announced plans for Phase III studies in two NSCLC settings. On May 9, it announced enrollment of the first U.S.-based patient in HARMONi, a registration-intent study with overall survival and progression-free survival as primary endpoints. These are post-quarter events, not Q1 results.
- Other risks include clinical and regulatory uncertainty, financing needs, and dependence on Akeso for drug supply. The filing reports no material legal proceedings and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective; it implemented a new ERP system during the quarter.
Important facts for investors to verify
- Clinical progress, trial design, enrollment, and regulatory plans for ivonescimab, including HARMONi and HARMONi-3.
- Cash burn and runway assumptions, future financing needs, and the timing and terms of any capital raise.
- Related-party note terms, interest costs, maturity obligations, and governance implications.
- Potential Akeso milestone and royalty obligations, plus drug-supply and manufacturing commitments.
- The extent of share dilution from the rights offering and any additional equity issuance.
- Progress and potential partnership outcomes for ridinilazole and other anti-infectives programs.